Abstract
Background: cognitive and executive function impairment is common in predialysis CKD patients and occurs in even young patients. It is a major cause of morbidity. It impairs quality of life, hampers decision making and self-management of patients. Although initially subtle but may herald future and increase the burden on caregivers. Hence modifiable risk factors for cognitive impairment needs to be identified.
Objective: To identify modifiable risk factors to prevent cognitive impairment in predialysis CKD patients. This will help to device a simple, reliable and non-invasive bedside marker to predict and prevent cognitive and executive functional impairment in patients of CKD.
Methods: 70 CKD patients as defined by K/DOQI guidelines (kidney disease outcome quality initiative group) having an estimated GFR (eGFR)<60ml/min/1.73sq.mrtre, who had not undergone renal replacement therapy at the time of presentation were chosen as subjects of the study. They were compared with equal number of age and sex matched controls. Cognitive and executive functions of all cases and controls were assessed by using 6-item cognitive impairment test, MMSE, Trail making test-A and Trial making Test-B. All subjects underwent extensive blood and urine investigations. Testosterone level (samples were taken at 9 Am after overnight fasting) was done by a solid-phase enzyme immune assay by XEMA kit.
Results: Serum testosterone mean value among cases was 1.94±1.17 and among control was 6.04 ±3.16 (p= 0.0005). Serum Testosterone levels was found to be significantly correlating with the impairment of cognitive function statistically (p value<0.005). Similarly, hyperuricemia also correlated with cognitive impairment in patients of CKD. (MMSE p =0.0001, 6CIT p =0.043 & TRAIL A &B p =0.0001). Impairment of cognitive function did not correlate statistically with any other parameter in this study. Multivariate regression analysis revealed that hyperuricemia correlated inversely and was the most important factor affecting cognitive function in predialysis CKD patients (r = - 0.4259, p =0.0002) followed by serum testosterone (r = 0.282, p=0.0181).
Conclusion: Early treatment of hyperuricemia and testosterone replacement therapy may go a long way in preventing the cognitive impairment in CKD patients.
Keywords: Cognitive impairment, Testosterone, Hyperuricemia,Predialysis CKD.
References
- Ulla KS, Janine G, Michaela V, Olga T, Andreas K, Heikebruck, et al. The prevalence, severity, and association with HbA1c and fibrinogen of cognitive impairment in chronic kidney disease. Kidney Int 2014;85:693-702.
- Relationship between total testosterone, cognitive function, depressive behavior, and sleep quality in chronic kidney disease patients not on dialysis. Clinexpnephrol 2013;17:59-65.
- McQuillan R, Jassal SV. Neuropsychiatric complications of kidney disease. Nat Rev Nephrol 2010;6:471-479.
- Sanchez-Roman S, Ostrosky-Solis F, Morales-Buenrostro LE, Nogues-Vizcaino MG, Alberu J, McClintock Sm. Neurocognitive profile of an adult sample with chronic kidney disease. J IntNeuro-Psycholsoc 2011;17:80-90
- Carrero JJ, Stenvinkel P, The Vulnerable man:impact of testosterone deficiency on the uraemic phenotype. Nephrol Dial Transplant 2012;27:4030-4041.
- Juan JC, Abdul RQ, Ayumu N, Stefan A, Paoloparini, BengtLindholm, et al, Nephrol Dial Transplant 2011;26:184-190.
- Handelsman DJ. Hypothalamic pituitary gonadal dysfunction in renal failure, dialysis and renal transplant. Endocr Rev 1985;6:151-182.
- Carrero JJ, Qureshi AR, Axelsson J. Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. J Int Med 2007;262:690-701.
- Schmidt A, Luger A, Horl WH. Sexual hormone abnormalities in male patients with renal failure. Nephrol Dial Transplant 2002;17:368-371.
- Dunkel L, Raivio T, Laine J. Circulating luteinizing hormone receptor inhibitors in boys with chronic renal Kidney Int 1997;51:777-784.
- Palmer BF. Outcomes associated with hypogonadism in men with chroni kidney disease. AdvChron kidney dis 2004;11:342-347.
- Kurella M, Yaffe K, Shiplak MG, Wenger NK. Chronik kidney disease and cognitive impairment in menopausal women. Am J Kidney Dis 2005;45:66-76.
- Kurella M, Wadley V, Yaffe K, McClure LA, Howard G, Go R, et al. kidney function and cognitive impairment in US adults:the reason for geographic and racial difference in stroke(REGARDS) study. Am J kidney Dis 2008;52(2):227-234.
- Janowsky JS. Thinking with your gonads: testosterone and cognition. Trends in Cognitive Sciences 2006;10:77–82.
- Hogervorst E, Bandelow S & Moffat SD. Increasing testosterone levels and effects on cognitive functionsin elderly men and women: a review. Current Drug CNS and Neurological Disorders 2005;4:531540.
- Tirassa P, Thiblin I, Agren G, Vigneti E, Aloe L &Stenfors C. Highdose anabolic androgenic steroidsmodulate concentrations of nerve growth factor andexpression of its low affinity receptor (p75-NGFr) inmale rat brain. Journal of Neuroscience Research1997;47:198–207.
- PouliotWA, Handa RJ & Beck SG. AndrogenModulates N-methyl-D-aspartate-mediateddepolarization in CA1 hippocampal pyramidal cells.Synapse 1996; 23: 10–19.
- Morse JK, DeKosky ST & Scheff SW. Neurotrophic effects of steroids on lesion induced growth in the II. Hormone replacement. ExperimentalNeurology 1992;118: 47–52.
- Ahlbom E, Prins GS & Ceccatelli S. Testosterone protects cerebellar granule cells from oxidative stress-induced cell death through a receptor mediated mecha-nism. Brain Research 2001;892:255–262.
- Hammond J, Le Q, Goodyer C, Gelfand M, Trifiro M & LeBlanc A. Testosterone-mediated neuroprotection through the androgen receptor in human primary neurons. Journal of Neurochemistry 2001;77: 1319–1326.
Corresponding Author
Dr Gangadhar
07 Mituna Block, Police Quarters, Tajsultanpur.
Gulbarga, Karnataka- 585104, India
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
DOI: https://dx.doi.org/10.18535/jmscr/v6i5.99
